LATAM Fabry Disease Will Be A Source Of Important Clinical Data

LATAM Fabry Disease

LATAM Fabry Disease is a genetic condition that affects the X chromosome, causing problems with the ability to produce an enzyme called alpha-galactosidase A. This enzyme is involved in breaking down a fatty substance known as globotriaosylceramide. In people with Fabry disease, this enzyme is not produced in sufficient amounts, allowing the substance to build up in the blood and in certain cell types.

It can affect the kidneys, the heart, and the central nervous system. It can also cause abdominal pain, diarrhea, and other digestive disorders. It can lead to a variety of health conditions, including kidney failure, fibrosis, and stroke.

LATAM Fabry Disease is most commonly inherited from a parent, whereas it can also occur in a person's children. It is more common in males than in females. Women with Fabry disease typically have a milder form of the disorder, with less severe symptoms. They may not have any symptoms.

The most common treatment for LATAM Fabry Disease is enzyme replacement therapy, which allows the body to break down fatty substances and normalizes its own ability to do so. There are other therapies available as well, including migalastat (Galafold), which stabilizes the enzymes.

The risk of cardiovascular diseases and stroke is higher in people with LATAM Fabry Disease. The abnormal GL-3 can cause damage tu0o different organs, putting the heart at greater risk for a heart attack or stroke. In patients with Fabry, there is also a greater risk for renal insufficiency.

The Fabry Registry in LATAM is one of the world's largest clinical registries for Fabry disease. Since its initial enrollment in 2002, the Registry has steadily increased in number. The Registry is a unique source of valuable information about Fabry disease. It is also a means to understand the nature of Fabry disease.

There were relatively few LATAM patients who provided detailed renal clinical data. The estimated glomerular filtration rate was 60 mL/m2/1.73m2. These numbers are largely lower than the estimated glomerular filtration rates of Fabry Registry patients worldwide. However, these results were not necessarily accompanied by a reduction in age at diagnosis.

Despite the fact that a small number of patients were able to provide detailed renal clinical data, the overall population of LATAM patients with Fabry disease had less severe renal disease than Fabry Registry patients /vworldwide. This may be due to the age of the overall patient population in LATAM. Patients in LATAM have a larger average family size. This may have contributed to the smaller age at diagnosis.

Pfizer Inc., and the University of Sao Paulo General Hospital collaborated in September 2020, for carrying out clinical trials for evaluating the diastolic myocardial elasticity in individuals suffering from Fabry disease.